Home LiteratureArticle Details
PMID: 16103142 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Journal of virology ·Vol. 79 ·No. 17 ·2005-09-00 ·Pages 10902-14

Forsell MN, Li Y, Sundbäck M, Svehla K, Liljeström P, Mascola JR, Wyatt R, Karlsson Hedestam GB

Abstract

The current lack of envelope glycoprotein immunogens that elicit broadly neutralizing antibody responses remains a major challenge for human immunodeficiency virus type 1 (HIV-1) vaccine development. However, the recent design and construction of stable soluble gp140 trimers have shown that some neutralization breadth can be achieved by using immunogens that better mimic the functional viral spike complex. The use of genetic delivery systems to drive the in vivo expression of such immunogens for the stimulation of neutralizing antibodies against HIV-1 may offer advantages by maintaining the quaternary structure of the trimeric envelope glycoproteins. Here, we describe the biochemical and immunogenic properties of soluble HIV-1 envelope glycoprotein trimers expressed by recombinant Semliki Forest virus (rSFV). The results presented here demonstrate that rSFV supports the expression of stable soluble gp140 trimers that retain recognition by conformationally sensitive antibodies. Further, we show that rSFV particle immunizations efficiently primed immune responses as measured after a single boost with purified trimeric gp140 protein, resulting in a Th1-biased antibody response. This differed from the Th2-biased antibody response obtained after repeated immunizations with purified gp140 protein trimers. Despite this difference, both regimens stimulated neutralizing antibody responses of similar potency. This suggests that rSFV may be a useful component of a viral vector prime-protein boost regimen aimed at stimulating both cell-mediated immune responses and neutralizing antibodies against HIV-1.

MeSH Terms
AIDS Vaccines/chemistry,immunology,metabolism Animals Cells, Cultured Female Gene Products, env/chemistry,immunology,metabolism HIV Antibodies/blood HIV Infections/blood,immunology Immunization Immunization Schedule Lymphocyte Count Mice Neutralization Tests Rabbits Semliki forest virus/genetics,metabolism Solubility Spleen/immunology Th1 Cells/immunology Vaccines, Synthetic/immunology,metabolism env Gene Products, Human Immunodeficiency Virus
Chemicals
AIDS Vaccines Gene Products, env HIV Antibodies Vaccines, Synthetic env Gene Products, Human Immunodeficiency Virus gp140 envelope protein, Human immunodeficiency virus 1
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Forsell Mattias N E
Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden.
Li Yuxing
Sundbäck Maria
Svehla Krisha
Liljeström Peter
Mascola John R
Wyatt Richard
Karlsson Hedestam Gunilla B
References (54)
54 references, click to expand
  1. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
    J Virol. 2000 Jan;74(2):627-43 PMID: 10623724
  2. High-level expression of the human neurokinin-1 receptor in mammalian cell lines using the Semliki Forest virus expression system.
    Eur J Biochem. 1994 Sep 15;224(3):917-21 PMID: 7523121
  3. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.
    J Virol. 2000 Jun;74(12):5716-25 PMID: 10823881
  4. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
    Virology. 2000 Jun 5;271(2):350-62 PMID: 10860888
  5. A trimeric structural domain of the HIV-1 transmembrane glycoprotein.
    Nat Struct Biol. 1995 Dec;2(12):1075-82 PMID: 8846219
  6. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.
    J Virol. 1996 Mar;70(3):1953-60 PMID: 8627721
  7. High-level expression of G protein-coupled receptors with the aid of the Semliki Forest virus expression system.
    J Recept Signal Transduct Res. 1995 Jan-Mar;15(1-4):23-32 PMID: 8903928
  8. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  9. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  10. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    J Virol. 1997 Oct;71(10):7198-206 PMID: 9311792
  11. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Science. 1998 Jun 19;280(5371):1884-8 PMID: 9632381
  12. Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
    J Virol. 1998 Sep;72(9):7620-5 PMID: 9696864
  13. Two-helper RNA system for production of recombinant Semliki forest virus particles.
    J Virol. 1999 Feb;73(2):1092-8 PMID: 9882310
  14. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.
    Vaccine. 1999 Feb 5;17(5):497-507 PMID: 10073729
  15. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    J Virol. 1999 May;73(5):4009-18 PMID: 10196297
  16. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.
    J Gen Virol. 1999 May;80 ( Pt 5):1189-98 PMID: 10355766
  17. T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.
    J Med Primatol. 2004 Oct;33(5-6):251-61 PMID: 15525326
  18. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins.
    Virology. 2004 Dec 5;330(1):233-48 PMID: 15527849
  19. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
    Virology. 2005 Jan 5;331(1):33-46 PMID: 15582651
  20. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
    J Virol. 2005 Jan;79(2):771-9 PMID: 15613305
  21. Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers.
    Virology. 2005 Feb 5;332(1):369-83 PMID: 15661168
  22. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.
    J Virol. 2005 Mar;79(5):2956-63 PMID: 15709015
  23. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    J Virol. 2005 Mar;79(6):3358-69 PMID: 15731230
  24. Energetics of the HIV gp120-CD4 binding reaction.
    Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9026-31 PMID: 10922058
  25. Type 1/Type 2 immunity in infectious diseases.
    Clin Infect Dis. 2001 Jan;32(1):76-102 PMID: 11118387
  26. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    J Virol. 2001 Jan;75(2):645-53 PMID: 11134278
  27. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.
    J Virol. 2001 Feb;75(3):1165-71 PMID: 11152489
  28. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus.
    J Infect Dis. 2001 May 1;183(9):1395-8 PMID: 11294672
  29. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.
    Vaccine. 2001 May 14;19(25-26):3526-36 PMID: 11348720
  30. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    J Virol. 2001 Jun;75(12):5526-40 PMID: 11356960
  31. A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model.
    Vaccine. 2001 Jul 16;19(28-29):3877-84 PMID: 11427261
  32. Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.
    Virology. 2001 Jul 5;285(2):204-17 PMID: 11437655
  33. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.
    J Virol. 2001 Aug;75(16):7470-80 PMID: 11462019
  34. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.
    J Virol. 2002 May;76(9):4634-42 PMID: 11932429
  35. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.
    J Virol. 2002 May;76(10):4810-21 PMID: 11967298
  36. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.
    J Virol. 2002 Aug;76(15):7760-76 PMID: 12097589
  37. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
    J Virol. 2002 Sep;76(17):8875-89 PMID: 12163607
  38. Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV.
    Vaccine. 2002 Dec 19;20 Suppl 4:A61-5 PMID: 12477430
  39. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.
    J Mol Biol. 2003 Jan 10;325(2):325-35 PMID: 12488098
  40. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
    J Virol. 2003 Mar;77(5):3119-30 PMID: 12584337
  41. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.
    Nat Med. 2003 Mar;9(3):343-6 PMID: 12579198
  42. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  43. Live viral vectors: Semliki Forest virus.
    Methods Mol Med. 2003;87:69-82 PMID: 12958450
  44. HIV vaccine design and the neutralizing antibody problem.
    Nat Immunol. 2004 Mar;5(3):233-6 PMID: 14985706
  45. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    J Virol. 2004 Jul;78(14):7490-7 PMID: 15220422
  46. Characterization of the conformational state and flexibility of HIV-1 glycoprotein gp120 core domain.
    J Biol Chem. 2004 Jul 16;279(29):30523-30 PMID: 15131118
  47. Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.
    J Gen Virol. 2004 Oct;85(Pt 10):2915-24 PMID: 15448353
  48. Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?
    Lancet. 1985 Nov 2;2(8462):1016-7 PMID: 2865493
  49. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Nature. 1990 Jun 14;345(6276):622-5 PMID: 2190095
  50. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
    J Virol. 1991 Feb;65(2):852-60 PMID: 1898972
  51. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.
    Biotechnology (N Y). 1991 Dec;9(12):1356-61 PMID: 1370252
  52. Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors.
    AIDS Res Hum Retroviruses. 1993 Oct;9(10):963-70 PMID: 8280479
  53. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    J Virol. 1994 May;68(5):3015-26 PMID: 7512157
  54. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Nat Med. 2000 Feb;6(2):207-10 PMID: 10655111
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2005-09-00
Pages
10902-14
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1193613
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com